As (non-malignant) B cells and monocytes express CD1d (Figure S2I), targeting type 1 NKT and Vγ9Vδ2-T cells to CD1d has a potential risk of on-target off-tumor toxicity. The gene discussed is CD1D; the disease is neoplasm.